How Much Body Weight Can You Lose on Wegovy?

Last reviewed: June 21, 2026

Last updated: June 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, originally developed for type 2 diabetes management, has become one of the most researched medications for weight loss. Clinical trials show that people using semaglutide consistently lose between 15% and 22% of their starting body weight within 68 weeks of treatment. Individual results vary based on genetics, lifestyle, and dose adjustment over time.

Average Weight Loss Results from Semaglutide Clinical Trials

The landmark STEP trials demonstrated that participants receiving semaglutide 2.4 mg weekly lost an average of 15.3 kg (about 34 pounds) over 68 weeks—representing roughly 15% of baseline body weight. A subset of patients achieved even greater reductions, with some losing 20-22% of their starting weight when combining medication with lifestyle modifications. These results represent significantly greater weight loss compared to placebo, where participants lost only 2-3 kg on average.

Weight loss typically begins within 2-4 weeks but becomes more noticeable at the 8-12 week mark as doses are gradually increased. The medication works by slowing stomach emptying and signaling fullness to the brain, which naturally reduces calorie intake without requiring extreme dietary restriction. Most patients experience their maximum weight loss between weeks 52 and 68 of continuous treatment.

Factors That Influence How Much Weight You'll Lose

The PlexusDx Precision Peptide Genetic Test ($298) analyzes FTO — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Timeline: When to Expect Weight Loss on Semaglutide

Week 1-4: Initial doses (typically 0.25-0.5 mg) may cause mild appetite suppression and gastrointestinal adjustments. Weight loss during this phase is usually minimal (0-2 pounds) as your body adapts to the medication. Nausea or constipation may occur but typically resolves within days.

Week 5-12: Dose escalation continues (0.5-1.0 mg), and appetite suppression becomes more pronounced. Most patients notice consistent weekly weight loss of 1-2 pounds during this window, totaling 5-10 pounds over eight weeks. Energy levels often improve as appetite-driven snacking decreases.

Week 13-52: Maintenance doses (1.7-2.4 mg weekly) produce steady, predictable weight loss of 0.5-1.5 pounds per week. Total weight loss by six months typically ranges from 15-35 pounds depending on starting weight and adherence. Plateaus lasting 2-4 weeks are normal and do not indicate treatment failure.

Semaglutide vs. Other GLP-1 Options for Weight Loss

PlexusDx offers semaglutide in injectable and oral forms, with injections typically producing faster, more consistent weight loss due to superior bioavailability. Compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan across all commitment tiers, with dosing flexibility that matches your treatment progression. Oral semaglutide ($289/month) offers convenience but requires specific timing and stomach acid conditions to absorb effectively, making it suitable for patients who cannot tolerate injections.

For patients seeking dual-pathway activation, PlexusDx also offers tirzepatide (a GLP-1 and GIP receptor agonist) at $289/mo month-to-month, or from $249/mo on the 6-month plan for injections, which targets additional appetite and metabolism pathways and may produce 20-25% weight loss in clinical data. The Precision Peptide Genetic Test identifies whether your genetic profile favors single or dual-mechanism therapy, optimizing your starting medication choice before committing to treatment.

Maintaining Weight Loss After Reaching Your Goal

Weight loss maintenance on semaglutide is sustainable as long as treatment continues—most patients maintain their achieved weight loss indefinitely with ongoing monthly injections. Unlike diet-only weight loss, where 80% of people regain weight within one year, semaglutide users show 60-70% weight retention long-term. This durability reflects the medication's sustained effect on appetite neurobiology rather than temporary dietary restriction.

Transitioning to a lower maintenance dose after reaching your goal can preserve results while reducing monthly costs and potential side effects. PlexusDx's pricing model ensures your dose adjustments never trigger price increases—your monthly cost remains flat regardless of whether you're titrating up or maintaining a lower therapeutic dose. Many patients stabilize at 1.0-1.7 mg weekly, lower than the 2.4 mg maximum, depending on their individual response and goals.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is 15-22% weight loss realistic for me, or is that just trial average?

No — the Precision Peptide Genetic Test does not predict your response to Wegovy or any specific medication. It analyzes pathway-level variants (FTO) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

How quickly can I expect to see results on semaglutide?

Most patients notice appetite reduction within 2-4 weeks and measurable weight loss by week 8-12. Full clinical benefit emerges by week 16-20 as doses reach therapeutic levels (1.0 mg and above). Weight loss continues steadily through week 52, then plateaus for most individuals, representing the completion of one treatment cycle.

Can I get semaglutide without insurance, and will the cost change as my dose increases?

Yes, PlexusDx serves all 50 states without insurance requirements. Compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan flat—your dose may increase, but your price won't. HSA and FSA accounts are eligible, and no membership fees apply, making treatment accessible regardless of insurance status.

What happens to my weight if I stop taking semaglutide?

Clinical data shows gradual weight regain after discontinuation, with most patients returning to baseline weight within 12-24 months if lifestyle changes are not sustained. Some patients maintain 30-50% of their weight loss long-term through diet and exercise alone. Ongoing treatment provides the most reliable weight maintenance for people with genetic predispositions to weight regain.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

PlexusDx Precision Peptide Genetic Test analyzes key variants (FTO rs9939609, GIPR rs1800437, and MC4R rs17782313) across 14 pathways to map your peptide responsiveness. The test ($298) identifies whether you're a high responder to GLP-1 monotherapy or might benefit from dual-mechanism tirzepatide instead, personalizing your medication selection before committing to long-term treatment.

Related Reading

• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight
• Wegovy For Losing Weight

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.